Taysha Gene Therapies (TSHA) Liabilities and Shareholders Equity (2019 - 2026)

Taysha Gene Therapies has reported Liabilities and Shareholders Equity for 8 years, with the latest figure at $300.4 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 117.08% year-over-year to $300.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 90.41% YoY) and the FY2025 annual result came in at $343.3 million, up 114.09% from the prior year.
• Liabilities and Shareholders Equity eased to $300.4 million in Q1 2026 per TSHA's latest filing, from $343.3 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $343.3 million in Q4 2025 and troughed at $81.5 million in Q2 2023.
• A 5-year average of $189.6 million and a median of $166.0 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity tumbled 53.76% in 2022, then surged 145.75% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $126.3 million in 2022, then jumped by 36.79% to $172.7 million in 2023, then declined by 7.16% to $160.4 million in 2024, then surged by 114.09% to $343.3 million in 2025, then decreased by 12.52% to $300.4 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $300.4 million, $343.3 million, and $316.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.